| I-005 Ludovica Aiello Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator Wednesday 10:20-11:50 |
| I-019 Annabelle Ballesta Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study Wednesday 10:20-11:50 |
| I-023 Imke Bartelink Enabling Tyrosine Kinase Inhibitor Precision Medicine through PET-Guided Physiologically-Based Pharmacokinetic Modeling Wednesday 10:20-11:50 |
| I-038 Myriam Briki Model-based meta-analysis of individual patient data from three independent datasets for the characterization of intravenous 5-fluorouracil population pharmacokinetics Wednesday 10:20-11:50 |
| I-049 Elio Campanile Supporting the development and optimization of mRNA-encoded therapeutics through a multiscale Physiologically Based Pharmacokinetic (PBPK) platform Wednesday 10:20-11:50 |
| I-054 Daniel Centanni Pharmacometric modeling to capture the time varying pharmacokinetics of PEG-asparaginase in acute lymphoblastic leukemia: A multi-protocol analysis from Nordic and Baltic countries Wednesday 10:20-11:50 |
| I-055 Maddalena Centanni Population pharmacodynamic characterization of automatically classified circulating tumor cells and vesicles and their relationship to survival in metastatic colorectal cancer patients Wednesday 10:20-11:50 |
| I-056 Marc Cerou A novel drug disease model in oncology to evaluate benefit-risk balance of tusamitamab ravtansine monotherapy Wednesday 10:20-11:50 |
| I-057 Anne Chain Population Pharmacokinetic and Exposure Response Analysis of Belzutifan in Advanced Renal Cell Carcinoma Wednesday 10:20-11:50 |
| I-062 Chengcong CHEN Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer Wednesday 10:20-11:50 |
| I-077 Miné De Kock Semi-mechanistic PK model development of Sabestomig for Dose Selection Wednesday 10:20-11:50 |
| I-083 Oleg Demin Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis Wednesday 10:20-11:50 |
| I-084 Oleg Demin Jr Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling Wednesday 10:20-11:50 |
| I-094 Vito Dozio Population PK and exposure-response modeling to support the design of trials with Debio 0123, a WEE1 inhibitor, in cancer patients Wednesday 10:20-11:50 |
| II-003 Anna Gebhard Pharmacokinetic–pharmacodynamic modeling and treatment simulation of maintenance therapy for childhood acute lymphoblastic leukemia Wednesday 15:20-16:50 |
| II-004 Eva Germovsek A semi-mechanistic model of preclinical VSV-GP(-Luc) viral dynamics in blood and tumour Wednesday 15:20-16:50 |
| II-009 Antonio Goncalves Operating characteristics of TGI metrics to support early Phase Ib decisions in unresectable hepatocellular carcinoma patients based on an historical Phase III study (IMbrave150) Wednesday 15:20-16:50 |
| II-019 Ikhlas Guermi Development of a pharmacokinetic-pharmacodynamic model to describe blood hepcidin levels in patients with myelofibrosis and assess target engagement of zilurgisertib, an ALK2 inhibitor Wednesday 15:20-16:50 |
| II-052 Alberto Ippolito PKPD model evaluating the ideal interplay between the PK and mechanism of activation of conditionally activated molecules Wednesday 15:20-16:50 |
| II-053 Khalid Iqbal A review of population PK and exposure-response models reported in FDA oncology submission documents Wednesday 15:20-16:50 |
| II-060 SEONGMEE JEONG Model informed dosage regimen optimization of anti-CD47 antibody using target-mediated drug disposition model. Wednesday 15:20-16:50 |
| II-075 Fenja Klima Quantifying the impact of CYP2D6 allele activity on Z-endoxifen formation leveraging the multi-study CEPAM database: Towards treatment optimisation of tamoxifen Wednesday 15:20-16:50 |
| II-077 Franziska Isabelle Kluwe Population Pharmacokinetic/Pharmacodynamic Modelling of Cytokine Releasing Syndrome (CRS) Events during T cell Engager Therapy Wednesday 15:20-16:50 |
| II-096 Apolline Lefevre Uncoupling tumor cell killing and cytokine release following T-cell engager administration with a mechanistic PKPD model Wednesday 15:20-16:50 |
| II-107 Han Liu Comparison between multistate and parametric time-to-event models for analysis of progression-free-survival (PFS) and overall survival (OS) in oncology trials Wednesday 15:20-16:50 |
| II-110 Sarah Lobet Revealing the complexity of monoclonal antibodies exposure-response relationship in metastatic colorectal cancer patients while mitigating confounding factors Wednesday 15:20-16:50 |
| III-009 Mathilde Marchand Comparison of tumor dynamics models and tumor growth inhibition metrics in support of decisions in early Phase Ib/II clinical oncology studies Thursday 09:50-11:20 |
| III-019 Anna Mc Laughlin Model-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2 Thursday 09:50-11:20 |
| III-022 Assil MERLAUD To quantify the association between tumor dynamics and overall survival across cancers: a Bayesian meta-analysis Thursday 09:50-11:20 |
| III-024 Anna Mishina A comparative benchmark study of empirical tumor size models in NSCLC clinical data Thursday 09:50-11:20 |
| III-033 Veronika Musatova Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371 Thursday 09:50-11:20 |
| III-034 Goutam Nair Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer Thursday 09:50-11:20 |
| III-039 Linh Nguyen Phuong Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors Thursday 09:50-11:20 |
| III-055 Orestis Papatryfonos Modelling of tumour growth with respect to the use of anti-cancer agents Thursday 09:50-11:20 |
| III-059 Blaise Pasquiers Translational modelling of tumor growth inhibition and treatment resistance for a molecule targeting apoptosis pathway Thursday 09:50-11:20 |
| III-063 Sophie Peigné Population pharmacokinetic analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate Thursday 09:50-11:20 |
| III-068 Yuan Pétermann Population pharmacokinetic model of encorafenib and binimetinb in real life settings Thursday 09:50-11:20 |
| III-075 Antoine Pitoy Estimation of phase III trial outcome in oncology using joint models of longitudinal biomarker and time-to-event data Thursday 09:50-11:20 |
| III-076 Vikram Prabhakar A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications Thursday 09:50-11:20 |
| III-078 Alicja Puszkiel Impact of resting energy expenditure on nivolumab pharmacokinetics and survival in metastatic non-small cell lung cancer patients Thursday 09:50-11:20 |
| III-079 Luyuan Qi A generic modeling framework for dose regimen optimization and patient selection in radioligand therapy Thursday 09:50-11:20 |
| III-082 Chetan Rathi Translational PK-Tumor Growth Inhibition (TGI) modeling of type 1 PRMT and PRMT5 inhibitor combination to predict clinical response Thursday 09:50-11:20 |
| III-091 Pascale Rietveld The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634 Thursday 09:50-11:20 |
| III-095 François Riglet Successful Establishment of Optimal Biological Dose (OBD) through PK/PD Modeling of BCL2/BIM Complex Disruption in Clinical Trials using a BCL-2 Inhibitor. Thursday 09:50-11:20 |
| III-097 Christelle Rodrigues Optimizing the Dose Escalation of a new anti-CD73 monoclonal antibody for target Inhibition: A Comprehensive Preclinical and Clinical Modelling Approach Thursday 09:50-11:20 |
| III-100 Davide Ronchi Translational modeling of tumor response to treatment: bridging preclinical to clinical studies Thursday 09:50-11:20 |
| III-110 Adriana Savoca Integration of clinical data and mechanistic model simulations highlights key parameters for design and selection of successful ADCs Thursday 09:50-11:20 |
| IV-003 Alejandro Serrano Alcaide Relationship between tumor growth and Treg activation status to optimize a previously published Immune oncology framework Thursday 15:00-16:30 |
| IV-012 Pooneh Soltantabar Elranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from MagnetisMM Studies Thursday 15:00-16:30 |
| IV-013 Meemansa Sood Lutathera dose determination and justification in adolescents via population PK and dosimetry modeling and simulation Thursday 15:00-16:30 |
| IV-014 Tomás Sou Population PK/PD modelling to evaluate the effect of siremadlin and disease progression on platelet dynamics in haematological malignancies Thursday 15:00-16:30 |
| IV-028 Sung Taewook Optimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment Thursday 15:00-16:30 |
| IV-029 Zhiyuan Tan Model-informed pazopanib dose optimization in real-world cancer patients Thursday 15:00-16:30 |
| IV-032 David Ternant Unveiling a “predator/prey” interplay of anti-CD19 CAR T-Cells and their targets in Relapsed/refractory DLBCL patients Thursday 15:00-16:30 |
| IV-033 Adrien Tessier Joint Modeling Of Longitudinal Circulating Tumor DNA And Survival In Metastatic Colorectal Cancer: A Promise Of Early Prediction Of Response In Oncology? Thursday 15:00-16:30 |
| IV-036 Hoai-Thu Thai A joint modeling approach leveraging intravenous data to support dose selection of subcutaneous isatuximab in combination with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma Thursday 15:00-16:30 |
| IV-053 Tamara van Donge Middle-out physiologically-based pharmacokinetic modeling to support pediatric dosing recommendation for alectinib, an ALK tyrosine kinase receptor inhibitor Thursday 15:00-16:30 |
| IV-062 Scott Van Wart Population Pharmacokinetic (PK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Serum M-Protein in an Ongoing Phase 1/2 Study of Modakafusp Alfa in Patients with Relapsed/Refractory Multiple Myeloma Thursday 15:00-16:30 |
| IV-092 Yin Cheong Wong Population pharmacokinetic/pharmacodynamic modeling to evaluate target suppression in patients with advanced solid tumors by ginisortamab, an anti-gremlin-1 monoclonal antibody Thursday 15:00-16:30 |
| IV-101 Simone Zannoni The impact of weekend dosing holidays on the evaluation of the sterilizing efficacy of different 4-drug combinations in a relapsing mouse model of Mycobacterium tuberculosis infection using a logistic Emax model Thursday 15:00-16:30 |
| IV-105 Stefan Zeiser A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor Thursday 15:00-16:30 |
| IV-112 Kirill Zhudenkov A model-based survival meta-analysis for indirect comparison of immune therapy efficacy in NSCLC Thursday 15:00-16:30 |
